Mantle Cell Lymphoma Clinical Trials in Los Angeles, California

6 studies are recruiting for mantle cell lymphoma in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

   This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody th…

   Stage

   Phase 3

   Ages

   60 and older

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Locations

   238 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT05976763 on ClinicalTrials.gov

2. Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

   The study is designed to examine the feasibility and safety of collecting autologous hematopoietic stem cells (HSCs) to be combined with CAR T-cell therapy for patients with relapsed/refractory (r/r) hematological disease. The study will evaluate feasibility of collecting the target dose of HSCs fr…

   Stage

   Phase 1

   Ages

   18 to 85

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Run by

   Joshua Sasine, MD, PhD

   See if you can join NCT05887167 on ClinicalTrials.gov

3. Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

   This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.

   Stage

   Phase 1

   Ages

   13 to 90

   Site

   Valkyrie Clinical Trials, Los Angeles, California

   Locations

   11 in total

   Run by

   Vironexis Biotherapeutics Inc.

   See if you can join NCT06533579 on ClinicalTrials.gov

4. A Long-term Extension Study of PCI-32765 (Ibrutinib)

   The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively rece…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of California Los Angeles, Los Angeles, California

   Locations

   175 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT01804686 on ClinicalTrials.gov

5. Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

   This phase II trial tests the safety and effectiveness of glofitamab given in combination with pirtobrutinib in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Glofitamab and obinut…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of California, Los Angeles, Los Angeles, California

   Locations

   3 in total

   Run by

   University of California, San Francisco

   See if you can join NCT06252675 on ClinicalTrials.gov

6. A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

   A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibit…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   California Research Institute, Los Angeles, California

   Locations

   16 in total

   Run by

   OncoNano Medicine, Inc.

   See if you can join NCT06022029 on ClinicalTrials.gov